Comprehensive genomic profiling linked to higher targeted therapy use, with Medicare patients lagging behind Optum and Illumina Inc. researchers documented that less than half of patients with newly diagnosed advanced cancers received any biomarker testing before starting treatment, a gap that persisted despite established guidelines recommending such assessments to guide therapy selection.
https://medicalxpress.com/news..../2025-07-comprehensi